DrugCendR Inc. to Present Phase I Plans on 2 Occasions During the JP Morgan Healthcare Conference in San Francisco Next Week
As DrugCendR is now preparing to transition from a preclinical to a clinical-stage company, the company will present details on their Phase I–ready lead compound CEND-1 – a highly innovative molecular mimicry agent that is able to activate a drug transport mechanism specifically in solid tumors. To date, there are more than 100 studies using DrugCendR’s proprietary technology, providing an unprecedented amount of preclinical validation / proof-of-concept.
San Diego, CA, January 04, 2018 --(PR.com)-- Next week is the most important week in healthcare as representatives from hundreds of biopharma companies arrive for meetings in and around San Francisco’s Union Square.
During the week, DrugCendR Inc. COO Harri Jarvelainen will present on 2 occasions – first at the China Showcase on Sunday, January 7, as then at the Biotech Showcase, on Wednesday, January 10.
The meeting details are as follows:
China Showcase:
Date: Sunday, January 7
Time: 3:15 PM
Room: Parc 55, Level 4, Cyril Magnin I
Biotech Showcase:
Date: Wednesday, January 10
Time: 10:15 AM
Room: Hilton San Francisco Union Square Hotel / Franciscan B
As DrugCendR is now preparing to transition from a preclinical to a clinical-stage company, the company will present details on their Phase I–ready lead compound CEND-1 – a highly innovative molecular mimicry agent that is able to activate a drug transport mechanism specifically in solid tumors. To date, there are more than 100 studies using DrugCendR’s proprietary technology, providing an unprecedented amount of preclinical validation / proof-of-concept. As the therapy progresses to human studies, the hope is that in addition to increasing the efficacies of anti-cancer therapies, this highly tumor-specific approach could be able to decrease the toxicities caused by the anti-cancer agents.
Biotech Showcase™ and China Showcase™ are investor and networking conferences produced by Demy-Colton and EBD Group.
Additional links and information: https://www.drugcendr.com/
During the week, DrugCendR Inc. COO Harri Jarvelainen will present on 2 occasions – first at the China Showcase on Sunday, January 7, as then at the Biotech Showcase, on Wednesday, January 10.
The meeting details are as follows:
China Showcase:
Date: Sunday, January 7
Time: 3:15 PM
Room: Parc 55, Level 4, Cyril Magnin I
Biotech Showcase:
Date: Wednesday, January 10
Time: 10:15 AM
Room: Hilton San Francisco Union Square Hotel / Franciscan B
As DrugCendR is now preparing to transition from a preclinical to a clinical-stage company, the company will present details on their Phase I–ready lead compound CEND-1 – a highly innovative molecular mimicry agent that is able to activate a drug transport mechanism specifically in solid tumors. To date, there are more than 100 studies using DrugCendR’s proprietary technology, providing an unprecedented amount of preclinical validation / proof-of-concept. As the therapy progresses to human studies, the hope is that in addition to increasing the efficacies of anti-cancer therapies, this highly tumor-specific approach could be able to decrease the toxicities caused by the anti-cancer agents.
Biotech Showcase™ and China Showcase™ are investor and networking conferences produced by Demy-Colton and EBD Group.
Additional links and information: https://www.drugcendr.com/
Contact
DrugCendR
Harri Jarvelainen
94492413025
https://www.drugcendr.com
Harri Jarvelainen
94492413025
https://www.drugcendr.com
Contact
Categories